Alpha Cognition (ACOG) announced that the United States Patent and Trademark Office has granted a new patent titled “Coated Tablets for pH-Dependent Release of Benzgalantamine.” This newly issued patent strengthens Alpha Cognition’s intellectual property portfolio by covering the composition of tablet formulations of benzgalantamine, further reinforcing the company’s existing patent protections. With this approval, Zunveyl has patent protection in the United States through 2044, supporting the company’s long-term growth strategy as it prepares for commercialization.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACOG:
- Alpha Cognition makes strategic personnel appointments to support ZUNVEYL launch
- Alpha Cognition, China Medical System enter exclusive Zunveyl licensing pact
- Alpha Cognition files to sell 1.45M common shares for holders
- Alpha Cognition Raises $52.8 Million in Stock Offering
- Alpha Cognition Reports Promising Data for Brain Injury Drug